

Sheehan's syndrome: a retrospective analysis

Swet Nisha^{1*}, Kalpana Singh², Shubhanti Kumari³

¹Senior Resident, Reproductive Medicine, IGIMS, Patna, Bihar, India

²Additional Professor, Reproductive Medicine, IGIMS, Patna, Bihar, India

³Assistant Professor, Reproductive Medicine, IGIMS, Patna, Bihar, India

Received: 05-01-2021 / Revised: 26-02-2021 / Accepted: 05-03-2021

Abstract

Introduction: Sheehan's syndrome is defined by varying degrees of anterior pituitary hormones deficiency due to postpartum ischemia of the pituitary gland after massive postpartum haemorrhage and shock. It can present during postpartum or several months or years following delivery. Endocrinologic manifestations of hypopituitarism reveal the deficiencies of specific hormones secreted from pituitary gland including hypoadrenalism, hypogonadism and hypogonadism. **Aims and Objectives:** To highlight the under diagnosed cases of Sheehan's syndrome. **Materials and Methods:** A retrospective analysis of Sheehan's syndrome was done over a period of 3 months from June 2019 to August 2019, at Reproductive Medicine department, IGIMS, Patna, Bihar, India; after clearance from institutional ethics committee. Case from 2010 to 2019 were taken. All the patients attending Reproductive Medicine OPD, Endocrinology OPD or presenting in Emergency with acute episodes of diarrhoea & vomiting and not maintaining BP, at IGIMS, Patna, were included. Se FSH, Se LH, Se Estradiol, Se Thyroid profile, Se Cortisol and ACTH stimulated cortisol along with CT Scan were done. We aimed to highlight the under diagnosed cases of Sheehan's syndrome (≥ 2 hormonal axis impairment). **Result:** A retrospective analysis was done. Total 15 cases were diagnosed. The mean age of presentation was 38.31 ± 5.9 years. Year of presentation following last delivery was 4-16 years. Mean duration was 7.67 ± 3.76 years. Secondary amenorrhoea and lactation failure were the most common clinical presentations. 11 patients presented with failure to resume menses following delivery and 3 had oligomenorrhoea following secondary amenorrhoea. 12 patients presented with lactation failure. All the 15 patients had history of severe PPH and 10 had home deliveries. The mean total tetraiodothyronine (T4), peak stimulated cortisol, stimulated growth hormone (GH), and prolactin (PRL) levels were low. Even in the presence of amenorrhoea the gonadotropins [follicle stimulating hormone (FSH) and luteinizing hormone (LH)] were inappropriately normal. Estrogen levels were low in 14 patients (93.33%). The most common hematological abnormality seen was anemia (53.33%) in 8 patients, while 5 patients (33.33%) had hyponatremia. 9 patients (60%) had empty sella turcica while 6 patients (40%) were having normal CT scan. BMD assessment ($n = 15$) was suggestive of low bone mass. After one year of hormonal replacement therapy, the QoL improved significantly ($P < 0.05$). **Conclusion:** Sheehan's syndrome is a frequent cause of hypopituitarism in developing countries and usually present with subtle clinical features. It causes multiple pituitary hormone deficiencies in all patients. It is prone to be missed and delayed diagnosis is common. Severe PPH, failure to lactate and cessation of menses are important clues. In patients with Sheehan's syndrome anemia, hyponatremia, and low bone mass were frequently seen. It is eminently treatable with gratifying response. The QoL improved significantly ($P < 0.05$) after one year of hormonal replacement therapy. With improved obstetric care we can prevent it.

Keywords: PPH, Sheehan's syndrome, Secondary amenorrhoea, lactation failure.

This is an Open Access article that uses a fund-ing model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>) and the Budapest Open Access Initiative (<http://www.budapestopenaccessinitiative.org/read>), which permit unrestricted use, distribution, and reproduction in any medium, provided original work is properly credited.

Introduction

Sheehan's syndrome remains a frequent obstetric complication in underdeveloped or developing countries due to relatively high prevalence of moderate to severe postpartum hemorrhage (PPH) and hypovolemic shock during or just after delivery [1,4]. Sheehan's syndrome (SS), a post partum pituitary necrosis, was first described by HL Sheehan in 1937. [5] The pituitary is one of the highly vascularized tissues in the body. Elevated concentration of estrogen during pregnancy results in hyperplasia of prolactin secreting cells or lactotrophs, leading to increase in pituitary volume by two-folds [6]. The pathophysiology of Sheehan's syndrome has been classically attributed to a transient hypoperfusion that provokes infarction, necrosis, and consequent dysfunction in a physiologically enlarged pituitary gland (due to pregnancy) [5,7,9].

At least 75-80% of pituitary is destroyed before clinical manifestations become evident. The extent of anterior pituitary hormone deficiency varies in different studies. The secretion of

growth hormone (GH) and prolactin get affected in 90-100% cases, while deficiencies in cortisol secretion, gonadotropins and thyroid stimulating hormone (TSH) ranged from 50 to 100% [10-12]. History of postpartum hemorrhage, failure to lactate and cessation of menses are important clues to the diagnosis. The frequency of Sheehan's syndrome has gradually decreased in developed countries due to improved obstetric care including treatment of hemodynamic complications with rapid blood transfusion and/or fluid replacement. In developing countries like India, home deliveries are still widely practised, thus, it is one of the leading causes of hypopituitarism [13]. The prevalence of Sheehan's syndrome in India is estimated to be 2.7-3.9% among parous women older than 20 years. [14] It's diagnosis usually takes months to years after the event [5,11]. Due to its delayed diagnosis, clinical presentation (which usually impairs quality of life), and potentially life-threatening complications (e.g. coma or death), sheehan's syndrome still remains important to pregnant women, clinicians, and public health services around the world [11]. Recently, several studies have assessed the role that autoimmunity could have in the pathophysiology of Sheehan's syndrome [15-18]. De Bellis et al. retrospectively detected anti-hypothalamic antibodies and anti-pituitary antibodies in the serum of

*Correspondence

Dr Swet Nisha

Senior Resident, Reproductive Medicine, IGIMS, Patna, Bihar, India

E-mail: swetnisha@gmail.com

Kumar et al

www.ijhcr.com

International Journal of Health and Clinical Research, 2021; 4(5):322-325

patients diagnosed with Sheehan’s syndrome (40% and 35%, resp.)[17].

Materials and Methods

The present study was conducted in the Department of Reproductive Medicine at IGIMS, Patna, Bihar, India, from June 2019 to August 2019 after clearance from institutional ethics committee. Cases from July 2010 to July 2019 were taken. Based on patient’s history (profound bleeding during or following the delivery, absence of postnatal lactation etc), physical examination, deficiency of one or more pituitary hormone and a CT scan for evaluation of the pituitary, diagnosis of Sheehan’s syndrome was done. Routine investigations like complete blood counts (CBC), thyroid function tests and basal hormone levels (for FSH, LH, prolactin, cortisol and GH) were performed for diagnosis.

For insulin tolerance test(ITT), regular insulin was used at a dose of 0.1 U/kg. The moment at which blood glucose level fell below 40 mg/dl or less(criterion of hypoglycaemia)was accepted as the 0time point and accordingly blood samples were taken at 0, 30, 60, 90 and 120 minutes for cortisol and GH determination. An increase in cortisol level of more than 21 g/dl and increase in GH level of more than 10g/dl,during the ITT test was consider significant. An MRI (1.5T) of pituitary was done. The patients were evaluated for BMD by dual energy x-ray absorptiometry (DEXA) of femoral neck, and lumbar spine (postero-anterior projection L1-4) at the time of the diagnosis of sheehan’s syndrome. With the help of Burckhardt

questionnaire, assessment of the quality of life was done; sixteen questions were asked to each patientboth before and after hormonal replacement therapy for one year (Prednisolone, levothyroxine and estrogen/progesterone in appropriate dosage).

Statistical analysis

Continuous data were summarized as Mean ± SD and discrete (categorical) values as numbers and percentages.

Results

The results are summarized in the tables below.

The mean age at diagnosis was 38.31±5.9 years, and mean diagnostic delay was 7.67± 3.76 years . Mean height, mean weight, mean BMI, mean systolic and diastolic BP, mean waist: hip circumference ratio and mean QOL are given in Table 1.

Anemia was the most common haematological abnormality found in 8 patients (53.33%). The most common electrolyte imbalance was hyponatremia seen in 5 patients (33.33%). Hypoglycaemia was seen in 2 patients (13.33%).

The common clinical manifestations found, were history of post partum haemorrhage in 100% of the patients, followed by secondary amenorrhea in 93.33% of patients, and lactation failure in 80% of patients.

Gonadotropins deficiency (LH and FSH) and estrogen deficiency was the most common hormonal abnormality found in the patients of Sheehan’s syndrome (93.33%), followed by prolactin deficiency and growth hormonal in 86.67% of patients, ACTH deficiency in 73.33% and TSH deficiency in 66.67% of patients.

Table 5 shows the bone mineral characteristics of patients with Sheehan’s syndrome. T-score, were found to be significantly reduced in lumbar spine (-2.9 ± 0.7) and femoral neck (-1.8 ± 0.7) as also the Z score; these were -1.7 ± 0.5, -1.3 ± 0.4 respectively in the patients of Sheehan’s syndrome. Severe osteoporosis (osteoporosis with fracture) was found in two patients (13.33%), osteoporosis in three patients (20%), osteopenia in four patients (26.67%), while the rest of the six patients had normal BMD.

Table 6 shows the quality of life in the patients of Sheehan’s syndrome before and after hormonal replacement therapy for one year. Before the start of therapy the score was 23 ± 7and it increased to 58.4 ± 7.6 after one year of hormonal replacement therapy.

Table 1: showing baseline parameters

Parameters	Mean±SD
Age at diagnosis(years)	38.31±5.9 years
Diagnostic Delay(years)	7.67± 3.76 years
Height(cm)	151±6.2
Weight(Kg)	46.4±7.2
BMI(Kg/m2)	21.6±3.4
Systolic BP(mmHg)	103.6±21.8
Diastolic BP(mmHg)	71.6±11.4
Waist: Hip circumference ratio	0.86±1.4
Quality of life scale (QOL) 112	26±7

Table 2: showing biochemical parameters

Biochemical Parameters	Mean±SD
Serum Sodium(135-145 mmol/L)	128.4±8.7
Serum Potassium(3.5-5.0 mmol/L)	4.1±1.3
Serum Calcium (8.7-10.2 mg/dL)	9.3±2.3
Serum Phosphorus(2.5-4.3 mg/dL)	3.1±0.7
Fasting plasma glucose (<100 mg/dL)	75.5±21.3
Hemoglobin (12-15 g/dL)	9.7±2.4

Table 3: showing signs and symptoms at presentation

Parameters	Number of patients	Percentage
Postpartum hemorrhage	15	100%
Secondary amenorrhea	14	93.33%
Lactation failure	12	80%
Asthenia	9	60%
Anemia	8	53.33%
Hyponatremia	5	33.33%
Hypoglycemia	2	13.33%

Table 4: Anterior Pituitary assessment (hormonal assessment of patients with Sheehan’s syndrome)

Parameters	Affected Patients	Percentage
------------	-------------------	------------

LH (3-12 IU/L)	14/15	93.33%
FSH (2-10 IU/L)	14/15	93.33%
Estrogen(<40 pg/ml)	14/15	93.33%
Stimulated GH (>3 ng/mL)	13/15	86.67%
PRL (9-21 ng/mL)	13/15	86.67%
Basal cortisol (<3 µg/dL)	11/15	73.33%
T4 (55-135 ng/mL)	10/15	66.67%
T3 (0.8-2 ng/mL)	10/15	66.67%

LH: Luteinizing hormone, FSH: Follicle stimulating hormone, PRL: Prolactin, GH: Growth hormone

Table 5: BMD

Cases	Age(years)	Lumbar spine (T- score)	Lumbar spine (Z- score)	Femoral neck (T- score)	Femoral neck (Z- score)
Sheehan's Syndrome BMD	38.31±5.9 years	(-2.9± 0.7) Severe Osteoporosis	-1.7 ± 0.5, Osteoporosis	(-1.8 ± 0.7) Osteopenia	-1.3±0.4 Normal

Table 6: QOL

Cases	Age(years)	Before HRT	After HRT for 1 year
Sheehan's Syndrome		23±7	58.4±7.6

Discussion

This retrospective study was done in the Department of Reproductive Biology at IGIMS, Patna, Bihar, from June 2019 to August 2019. Cases from July 2010 to July 2019 were included. Total fifteen patients were diagnosed; patients were evaluated for the baselines parameters, clinical presentation, hormonal assessment, bone mineral density and quality of life assessment during the study. The prevalence of Sheehan's syndrome among women of reproductive age in the Kashmir valley (Indian subcontinent) was estimated to be 3.2%[14]

Sheehan's syndrome's presentation may be acute or chronic. The diagnosis of the chronic form may be delayed for many years while acute form is very rare. This interval may be as long as 15 to 20 years[20] In the present study, the diagnostic delay was 7.67± 3.76 years, with the earliest detection after 4.8 years and the longest being a duration of 17 years. The delay in diagnosis is common because most of the patients with Sheehan's syndrome, don't show frank symptoms suggestive of pituitary involvement. Also, another contributing factor in the delay in diagnosis is the lack of awareness about Sheehan's syndrome among physicians.

In the present study the most common presentations of patients with Sheehan's syndrome was history of post partum haemorrhage (100%), followed by secondary amenorrhea (93.33%), lactation failure in 80% of patients, asthenia in 60% of patients, anemia in 53.33% of patients, hyponatremia in 33.33% and hypoglycemia in 13.33% of patients. The results of our study correspond to various studies done previously[14,21-27].

Thus, the most common electrolyte imbalance was hyponatremia (33.33%), corresponding to the study done by Dokmetas *et al*[11] The cause of anemia is believed to be due to deficient anterior pituitary hormones or absence of some other yet unidentified factors normally secreted from the pituitary.

Somatotropes (GH) and lactotrophs (PRL) are the most common cells involved in Sheehan's syndrome, followed by the gonadotrophs (LH and FSH), corticotrophs and thyrotropes. Various studies have reported partial insufficiency in 10-30% of the patients and complete pituitary insufficiency in 70-90% of the patients[14,28] Involvement of posterior pituitary is very rare but may be present in small number of patients[29,30]. In the present study, the most common hormone deficiency was of gonadotropins in 93.33% of patients followed by GH, prolactin, ACTH, and thyrotropes in 86.67%, 86.67%, 73.33%

and 66.67% of patients. Diabetes insipidus was not found in any of the patients.

The BMD of all the patients were recorded after diagnosis. Severe osteoporosis (osteoporosis with fracture) was seen in two patients (13.33%), osteoporosis in three patients (20%), osteopenia in four patients (26.67%), and normal BMD was found in the rest of six patients. Results of the present study are comparable to the study done by Gokalp *et al*. [31] radiological imaging also aids in the diagnosis of Sheehan's syndrome; An empty sella, as typical feature of Sheehan's syndrome was described by Fleckman *et al*. [32] It has been shown by various studies that compared to the normal controls, sella volumes decrease in patients with Sheehan's syndrome. [33] CT scan of the pituitary was done in all the patients. Nine patients (60%) had an empty sella while six patients (40%) had a normal CT scan. With the help of Burckhardt questionnaire the quality of life assessment was done; [34] sixteen questions were asked to each patient both before and after hormonal replacement therapy for one year. After one year, the score improved significantly from 23±7 to 58.4±7.6. Previously an improvement in score was reported only with GH replacement therapy [35] but in the present study, patient's scores for quality of life improved significantly without GH replacement therapy i.e after substitution with levothyroxine, prednisolone, and estrogen/progesterone.

Conclusion

Sheehan's syndrome has been usually described to affect pregnant woman after moderate to profound hypovolemic shock during delivery. However, it is usually diagnosed months to years after the hemorrhagic event due to its subtle symptoms and clinicians ignorance. We can prevent Sheehan's syndrome with improved obstetric care. Also it is eminently treatable with gratifying response. Thus, in developing countries obstetric care should be upgraded.

References

1. Velasco-Murillo V and Navarrete-Hernandez E. Maternal mortality in the IMSS: an analysis from the perspective of mortality and lethality. *Cirugia y Cirujanos*, 2006;74: 21-26.
2. Prick B W, auf Altenstadt J F S, Hukkelhoven C W P M et al. Regional differences in severe postpartum hemorrhage: a nationwide comparative study of 1.6 million deliveries. *BMC Pregnancy and Childbirth*, 2015;15: 43.
3. DeSouza M D L, Laurenti R, Knobel R, Monticelli M, Brüggemann O M, and Drake E. Maternal mortality due to

- hemorrhage in Brazil. *Revista Latino-Americana de Enfermagem*, 2013; 21: 711–718.
4. Feinberg E C, Molitch M E, Endres L K, and Peaceman A M. The incidence of Sheehan's syndrome after obstetric haemorrhage. *Fertil and Steril*, 2005; 84:975–979.
 5. Sheehan H L. Post-partum necrosis of the anterior pituitary. *J Path and Bact*, 1937;45: 189–214.
 6. Scheithauer BW, Sano T, Kovacs KT, Young WF Jr, Ryan N, Randall RV. The pituitary gland in pregnancy: A clinicopathologic and immunohistochemical study of 69 cases. *Mayo Clin Proc* 1990;65:461-74.
 7. Carmichael J D. Update on the diagnosis and management of hypophysitis. *Current Opinion in Endocrinology & Diabetes and Obesity*, 2012;19: 314–321.
 8. Kilicli F, Dokmetas H S, and Acibucu F. Sheehan's syndrome. *Gynecol Endocrinol*, 2013;29: 292–295.
 9. Gonzalez J G, Elizondo G, Saldivar D, Nanez H, Todd L E, and Villarreal J Z. Pituitary gland growth during normal pregnancy: an in vivo study using magnetic resonance imaging. *Am J Med*, 1988;85:217–220.
 10. Sert M, Tetiker T, Kirim S, Kocak M. Clinical report of 28 patients with Sheehan's syndrome. *Endocr J* 2003;50:297-301.
 11. Dökmetaş H S, Kilicli F, Korkmaz S, and Yonem O. Characteristic features of 20 patients with Sheehan's syndrome. *Gynecol Endocrinol*, 2006; 22:279–283.
 12. Banzal S, Ayoola EA, Banzal S. Sheehan's syndrome in Saudi Arabia. *Int J Gynaecol Obstet* 1999;66:181-2.
 13. Chatterjee P, Mukhopadhyay P, Pandit K, Roychowdhury B, Sarkar D, Mukherjee S, *et al.* Profile of hypopituitarism in a tertiary care hospital of eastern India-is quality of life different in patients with growth hormone deficiency? *J Indian Med Assoc* 2008;106:384-5, 388.
 14. Zargar AH, Singh B, Laway BA, Masoodi SR, Wani AI, Bashir MI. Epidemiologic aspects of postpartum pituitary hypofunction (Sheehan's syndrome). *Fertil Steril* 2005;84:523-8.
 15. Atmaca H, Araslı M, Yazıcı Z A, Armutçu F, and Tekin I O. Lymphocyte subpopulations in Sheehan's syndrome. *Pituitary*, 2013;16: 202–207.
 16. Bellastella A, Bizzarro A, Coronella C, Bellastella G, Sinisi A A, and De Bellis A. Lymphocytic hypophysitis: a rare or underestimated disease? *Eur J Endocrinol*, 2003;149: 363–376.
 17. De Bellis A, Kelestimur F, Agostino Sinisi A *et al.* Anti-hypothalamus and anti-pituitary antibodies may contribute to perpetuate the hypopituitarism in patients with Sheehan's syndrome. *Eur J Endocrinol*, 2008;158: 147–152.
 18. Goswami R, Kochupillai N, Crock P A, Jaleel A, and Gupta N. Pituitary autoimmunity in patients with Sheehan's syndrome. *J Clin Endocrinol & Metab*, 2002; 87: 4137–4141.
 19. Burckhardt CS, Woods SL, Schultz AA, Ziebarth DM. Quality of life of adults with chronic illness: A psychometric study. *Res Nurs Health* 1989;12:347-54.
 20. De Groot LJ. *Textbook of endocrinology*. 2nd ed. Philadelphia: Saunders; 1989;2:431-2.
 21. Collins ML, O'Brien P, Cline A. Diabetes insipidus following obstetric shock. *Obstet Gynecol* 1979;53:16S-7.
 22. Wang SY, Hsu SR, Su SL, Tu ST. Sheehan's syndrome presenting with early postpartum congestive heart failure. *J Chin Med Assoc* 2005;68:386-91.
 23. Weston G, Chaves N, Bowditch J. Sheehan's syndrome presenting post-partum with diabetes insipidus. *Aust N Z J Obstet Gynaecol* 2005;45:249-50.
 24. Kale K, Nihalani N, Karnik N, Shah N. Postpartum psychosis in a case of sheehan's syndrome. *Indian J Psychiatry* 1999;41:70-2.
 25. Boulanger E, Pagniez D, Roueff S, Binaut R, Valat AS, Provost N, *et al.* Sheehan syndrome presenting the early postpartum hyponatraemia. *Nephrol Dial Transplant* 1999;14:2714-5.
 26. Sas AM, Meynaar IA, Laven JS, Bakker SL, Feelders RA. Irreversible coma following hypoglycemia in Sheehan syndrome with adrenocortical insufficiency. *Ned Tijdschr Geneesk* 2003;147:1650-3.
 27. Bunch TJ, Dunn WF, Basu A, Gosman RI. Hyponatremia and hypoglycemia in acute Sheehan's syndrome. *Gynecol Endocrinol* 2002;16:419-23.
 28. Haddock L, Vega LA, Aguilo F, Rodriguez O. Adrenocortical, thyroidal and human growth hormone reserve in Sheehan's syndrome. *Johns Hopkins Med J* 1972;131:80-99.
 29. Bayram F, Ünlühizarci K, Keleştimur F. A retrospective investigation of the patients with sheehan's syndrome seen in erciyes university medical school hospital during the last 7 years. *Tur JEM* 1996;6:279-91.
 30. Briet JW. Diabetes insipidus, Sheehan's syndrome and pregnancy. *Eur J Obstet Gynecol Reprod Biol* 1998;77:201-3.
 31. Gokalp D, Tuzcu A, Bahceci M, Arıkan S, Özmen CA, Cil T. Sheehan's syndrome and its impact on bone mineral density. *Gynecol Endocrinol* 2009;25:344-9.
 32. Fleckman AM, Schubart UK, Danziger A, Fleischer N. Empty sella of normal size in Sheehan's syndrome. *Am J Med* 1983;75:585-91.
 33. Bakiri F, Bendib SE, Maoui R, Bendib A, Benmiloud M. The sella turcica in Sheehan's syndrome: Computerized tomographic study in 54 patients. *J Endocrinol Invest* 1991;14:193-6.
 34. Gilchrist FJ, Murray RD, Shalet SM. The effect of long-term untreated growth hormone deficiency (GHD) and 9 years of GH replacement on the quality of life (QoL) of GH-deficient adults. *Clin Endocrinol (Oxf)* 2002;57:363-70.
 35. Hoffman AR, Kuntze JE, Baptista J, Baum HB, Baumann GP, Biller BM, *et al.* Growth hormone (GH) replacement therapy in adult-onset gh deficiency: Effects on body composition in men and women in a double-blind, randomized, placebo controlled trial. *J Clin Endocrinol Metab* 2004;89:2048-56.

Conflict of Interest: Nil

Source of support: Nil